Elevar Therapeutics Achieves 23.8 Months Median Overall Survival in First-Line Unresectable Hepatocellular Carcinoma
In a significant development for the treatment of unresectable hepatocellular carcinoma (uHCC), the combination of camrelizumab and rivoceranib has demonstrated sustained long-term survival benefits over sorafenib, according to the Phase 3 CARES-310 study. Elevar Therapeutics, Inc. announced these findings, which will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Landmark Survival Analysis
The final analysis of the CARES-310 study showed that the combination therapy of camrelizumab and rivoceranib resulted in the longest median overall survival (OS) ever reported in a global Phase 3 uHCC trial. Median OS was extended to approximately two years, with more than one-third of patients surviving beyond three years. Specifically, median OS was 23.8 months for the combination therapy compared to 15.2 months for sorafenib. The OS rates at 24 and 36 months were also higher for the combination therapy, standing at 49.0% and 37.7%, respectively, against 36.2% and 24.8% for sorafenib.
Clinical and Statistical Significance
The prolonged survival was not only statistically significant but also clinically meaningful. The hazard ratio for OS was 0.64, with a p-value of less than 0.0001, indicating a 36% reduction in the risk of death compared to sorafenib. This survival benefit was consistent across various subgroups, including different geographical regions, races, and etiologies of the disease.
Safety Profile and Progression-Free Survival
The combination therapy also maintained a manageable safety profile, reinforcing its viability as a first-line treatment option. Earlier interim analysis had already indicated significant progression-free survival (PFS) benefits, and these findings were corroborated in the final analysis.
Study Design and Patient Population
The CARES-310 study was a randomized, open-label international Phase 3 trial involving 543 patients with unresectable or metastatic HCC who had not received prior systemic therapy. Participants were assigned in a 1:1 ratio to receive either the combination of camrelizumab and rivoceranib or sorafenib. The trial was conducted across 95 sites in 13 countries, making it a robust study with diverse patient representation.
Mechanisms of Action
Camrelizumab is a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, a pathway crucial for immune checkpoint inhibition. Rivoceranib is a potent inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays a key role in tumor angiogenesis. The synergy between these two agents contributes to their effectiveness in combating uHCC.
Broader Implications
This study marks the first time that a combination of immunotherapy and an anti-angiogenic tyrosine kinase inhibitor has shown significant survival benefits over the standard TKI treatment in first-line uHCC therapy. The results could potentially shift the treatment paradigm, providing a new standard of care for a condition that has long been associated with poor prognosis and limited treatment options.
Future Directions
Further research will continue to explore the full potential of this combination therapy. Additional data from the CARES-310 study will be available in upcoming publications, focusing on aspects like the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as indicators of treatment efficacy.
In summary, the Phase 3 CARES-310 study has set a new benchmark in the treatment of unresectable hepatocellular carcinoma, offering hope for improved patient outcomes with the combination of camrelizumab and rivoceranib.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
